Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
Zong Sheng Guo, Zuqiang Liu, David L. Bartlett
Frontiers in Oncology (2014) Vol. 4
Open Access | Times Cited: 264

Showing 1-25 of 264 citing articles:

The role of necroptosis in cancer biology and therapy
Yitao Gong, Zhiyao Fan, Guopei Luo, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 842
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H.C. Baumeister, Gordon J. Freeman, Glenn Dranoff, et al.
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 539-573
Closed Access | Times Cited: 836
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp, Laura Senovilla, Ilio Vitale, et al.
OncoImmunology (2014) Vol. 3, Iss. 9, pp. e955691-e955691
Open Access | Times Cited: 756
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi‐Boateng, Jessica L. Pettigrew, Young Kwok, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 7, pp. 419-432
Closed Access | Times Cited: 361
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Qingyang Lei, Dan Wang, Kai Sun, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 338
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu, Roshni Ravindranathan, Paweł Kaliński, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 311
Toxicity of Nanomaterials: Exposure, Pathways, Assessment, and Recent Advances
Priyanka Ganguly, Ailish Breen, Suresh C. Pillai
ACS Biomaterials Science & Engineering (2018) Vol. 4, Iss. 7, pp. 2237-2275
Closed Access | Times Cited: 282
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Yao Xiao, Tian Zhang, Xianbin Ma, et al.
Advanced Science (2021) Vol. 8, Iss. 24
Open Access | Times Cited: 261
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Zong Sheng Guo, Binfeng Lu, Zongbi Guo, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 252
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Enyong Dai, Zhi Zhu, Shudipto Wahed, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 194
Oncolytic virotherapy: basic principles, recent advances and future directions
Danni Lin, Yinan Shen, Tingbo Liang
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 172
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Yaomei Tian, Daoyuan Xie, Yang Li
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 171
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
Jing Ma, Mohanraj Ramachandran, Chuan Jin, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 145
CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma
Guoqing Wang, Zongliang Zhang, Kunhong Zhong, et al.
Molecular Therapy (2022) Vol. 31, Iss. 1, pp. 134-153
Open Access | Times Cited: 119
A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis
Wen Su, Wei Qiu, Shu‐Jin Li, et al.
Advanced Materials (2022) Vol. 35, Iss. 11
Closed Access | Times Cited: 72
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Simona Ruxandra Volovăț, Dragoş Viorel Scripcariu, Ingrid-Andrada Vasilache, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1180-1180
Open Access | Times Cited: 22
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
Markéta Skaličková, Katerina Hadrava Vanova, Ondřej Uher, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Irena Adkins, Jitka Fučíková, Abhishek D. Garg, et al.
OncoImmunology (2014) Vol. 3, Iss. 12, pp. e968434-e968434
Open Access | Times Cited: 183
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Chrisann Kyi, Michael A. Postow
Immunotherapy (2016) Vol. 8, Iss. 7, pp. 821-837
Open Access | Times Cited: 150
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
Sébastien Anguille, Evelien Smits, Christian Bryant, et al.
Pharmacological Reviews (2015) Vol. 67, Iss. 4, pp. 731-753
Open Access | Times Cited: 144
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
Joshua D. Freedman, Margaret R. Duffy, Janet Lei-Rossmann, et al.
Cancer Research (2018) Vol. 78, Iss. 24, pp. 6852-6865
Open Access | Times Cited: 144
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Rocio García‐Carbonero, Ramón Salazar, Ignacio Durán, et al.
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 138
Designing and Building Oncolytic Viruses
Justin W. Maroun, Miguel Ángel Muñoz-Alía, Arun Ammayappan, et al.
Future Virology (2017) Vol. 12, Iss. 4, pp. 193-213
Open Access | Times Cited: 134
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
Bernardo L. Rapoport, Ronald Anderson
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 4, pp. 959-959
Open Access | Times Cited: 132
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin, Jacob Ricca, Svetlana Sadekova, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 4, pp. 1413-1428
Open Access | Times Cited: 130
Page 1 - Next Page

Scroll to top